Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing.
Image: Amphivena closes $62m Series C financing to expand clinical development of AMV564 into solid tumors. Photo: courtesy of rawpixel from Pixabay.
Subscribe to our email newsletter
The round was co-led by NanoDimension and Qiming Venture Partners USA, and included new investors Clough Capital, Aju IB, Korys Merieux, Kaitai Capital, Industrial Investors, Nawton Limited and insiders MPM Capital, funds managed by Tekla Capital Management LLC and Franklin Berger.
“AMV564 is a T cell engager that selectively eliminates myeloid-derived suppressor cells (MDSC) in cancer patients while sparing normal neutrophils and monocytes. Its unique activity and excellent safety profile positions AMV564 well, as monotherapy or in combination with other agents, for the treatment of hematologic malignancies and solid tumors,” said Jeanmarie Guenot, Ph.D., Amphivena Chief Executive Officer and President.
“The Series C financing is an endorsement by new and existing investors of our leadership in the evolving T cell engagement space,” said Peter Van Vlasselaer, Ph.D., Executive Chairman. “This funding enables us to study the therapeutic impact of selective MDSC removal in both hematologic and solid cancers and to advance AMV564 and our novel T cell engagement portfolio to the forefront of immuno-oncology.”
Source: Company Press Release
